USA - NASDAQ:MIRA - US60458C1045 - Common Stock
The current stock price of MIRA is 1.62 USD. In the past month the price increased by 29.6%. In the past year, price increased by 47.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 49.71 | 759.85B | ||
JNJ | JOHNSON & JOHNSON | 18.61 | 465.34B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.07 | 262.58B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.85 | 254.43B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 13.94 | 241.59B | ||
MRK | MERCK & CO. INC. | 11.01 | 211.79B | ||
PFE | PFIZER INC | 7.23 | 139.35B | ||
SNY | SANOFI-ADR | 11.4 | 123.36B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.48 | 88.81B | ||
GSK | GSK PLC-SPON ADR | 9.74 | 88.32B | ||
ZTS | ZOETIS INC | 23.16 | 63.84B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 48.41 | 44.34B |
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
MIRA PHARMACEUTICALS INC
1200 Brickell Avenue, Suite 1950 #1183
Miami FLORIDA US
Employees: 3
Phone: 18133695150
The current stock price of MIRA is 1.62 USD. The price decreased by -10% in the last trading session.
The exchange symbol of MIRA PHARMACEUTICALS INC is MIRA and it is listed on the Nasdaq exchange.
MIRA stock is listed on the Nasdaq exchange.
7 analysts have analysed MIRA and the average price target is 18.11 USD. This implies a price increase of 1017.59% is expected in the next year compared to the current price of 1.62. Check the MIRA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MIRA PHARMACEUTICALS INC (MIRA) has a market capitalization of 30.89M USD. This makes MIRA a Nano Cap stock.
MIRA PHARMACEUTICALS INC (MIRA) currently has 3 employees.
MIRA PHARMACEUTICALS INC (MIRA) has a support level at 1.39 and a resistance level at 1.76. Check the full technical report for a detailed analysis of MIRA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MIRA does not pay a dividend.
MIRA PHARMACEUTICALS INC (MIRA) will report earnings on 2025-11-12, before the market open.
MIRA PHARMACEUTICALS INC (MIRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
The outstanding short interest for MIRA PHARMACEUTICALS INC (MIRA) is 1.32% of its float. Check the ownership tab for more information on the MIRA short interest.
ChartMill assigns a technical rating of 6 / 10 to MIRA. When comparing the yearly performance of all stocks, MIRA is one of the better performing stocks in the market, outperforming 81.65% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to MIRA. The financial health of MIRA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months MIRA reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 44.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -894.29% | ||
ROE | -1362.54% | ||
Debt/Equity | 0 |
7 analysts have analysed MIRA and the average price target is 18.11 USD. This implies a price increase of 1017.59% is expected in the next year compared to the current price of 1.62.